. 2014 Oct 11;64(2):149–159. doi: 10.1007/s00262-014-1618-8

Table 3.

The MDSC levels in 16 patients with pancreatic cancer undergoing chemotherapy were measured

Patient	HLADR^neg/CD33⁺	HLADR^neg/CD33⁺/CD15⁺/CD11b⁺	HLADR^neg/CD33⁺/CD14⁺/CD11b⁺	HLADR^neg/CD33⁺/CD14^neg/CD15^neg	Stage	ECOG	CA-19-9
1	1.51	1.37	0.60	0.17	3	1	909.53
2	0.97	0.65	0.45	0.29	1	0	<15
3	0.60	0.28	0.23	0.27	2	0	19.7
4	0.59	0.47	0.43	0.15	4	1	11,658
5	3.36	2.35	0.40	1.11	4	0	3,072.82
6	4.31	3.57	1.65	0.80	4	2	<15
7	3.00	0.90	1.26	1.56	4	1	220.74
8	17.9	8.95	6.87	8.32	4	3	6,300
9	3.30	2.18	1.15	1.19	3	1	653.57
10	1.18	0.57	0.36	0.71	4	1	47,901
11	4.35	3.14	0.02	1.82	4	1	59,595
12	3.67	2.42	1.53	1.16	4	2	314.38
13	8.05	7.27	5.92	0.64	3	1	3,064
14	3.49	2.97	0.25	0.49	3	0	64.82
15	2.22	0.81	0.50	1.40	2	2	11,976.55
16	5.07	4.44	0.16	0.75	4	2	9,072

Of these 16 patients, one patient had stage I disease, two patients had stage II disease, four patients had stage III disease, and nine patients had stage IV disease